Loading
A whole-genome blood test for leftover cancer from AccuraGen that corrects sequencing errors read by read, so it can add up thousands of a tumour's mutations.
AccuScan was described by AccuraGen of San Jose, California, with Shanghai YunSheng Medical Laboratory, in EMBO Molecular Medicine in 2024 (Li et al.). The authors report an error rate of 4.2 x 10^-7 and an analytical sensitivity down to 10^-6 circulating variant allele frequency at 99 per cent sample-level specificity. In colorectal cancer it showed 90 per cent landmark sensitivity and 100 per cent specificity for relapse within six weeks of surgery; in oesophageal cancer, 67 per cent sensitivity and 100 per cent specificity one week after surgery.
The full text's dilution data put the dependable limit near 10 parts per million: detection at 10 parts per million was 96 per cent with 10,000 markers and 100 per cent with 20,000, and in a melanoma dilution series two of three replicates were detected at 5 parts per million and one of three at 2. Commercial status was not confirmed.
Whole-genome sequencing of cell-free DNA in which each read is error-corrected on its own, so thousands of a tumour's mutations found by tumour whole-genome sequencing can be counted across the genome without a personalised panel.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AccuScan" OR ABSTRACT:"AccuScan" OR TITLE:"AccuraGen AccuScan" OR ABSTRACT:"AccuraGen AccuScan") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AccuScan, not a curated reading list.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Tumour-informed versus tumour-naive ctDNA assays, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing and the tags test, mrd.
Shares Genome-wide ctDNA mutation integration (MRDetect, MRD-EDGE), Tumour-informed versus tumour-naive ctDNA assays, Whole-exome & whole-genome sequencing, Minimal / molecular residual disease (MRD) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/